Doximity Future Growth
Future criteria checks 3/6
Doximity is forecast to grow earnings and revenue by 14.1% and 11.2% per annum respectively. EPS is expected to grow by 9.6% per annum. Return on equity is forecast to be 21.3% in 3 years.
Key information
14.1%
Earnings growth rate
9.6%
EPS growth rate
Healthcare Services earnings growth | 27.5% |
Revenue growth rate | 11.2% |
Future return on equity | 21.3% |
Analyst coverage | Good |
Last updated | 18 Feb 2025 |
Recent future growth updates
Recent updates
Doximity Q3 Earnings: Outpacing Even Management's Expectations
Feb 10When Should You Buy Doximity, Inc. (NYSE:DOCS)?
Jan 24Doximity: Upgraded To Buy Amid Promising Growth And Strong Execution
Jan 13Here's Why We Think Doximity (NYSE:DOCS) Is Well Worth Watching
Jan 06Doximity: Strong Fundamentals And Growth Potential Makes It Attractive
Dec 06Doximity (NYSE:DOCS) Knows How To Allocate Capital
Dec 01Earnings Not Telling The Story For Doximity, Inc. (NYSE:DOCS) After Shares Rise 34%
Nov 13Does This Valuation Of Doximity, Inc. (NYSE:DOCS) Imply Investors Are Overpaying?
Nov 02Is Doximity, Inc. (NYSE:DOCS) Potentially Undervalued?
Oct 15Doximity: Downgrade To Hold On Valuation Concerns
Oct 03Here's Why Doximity (NYSE:DOCS) Has Caught The Eye Of Investors
Sep 23There's Reason For Concern Over Doximity, Inc.'s (NYSE:DOCS) Massive 27% Price Jump
Aug 18Doximity (NYSE:DOCS) Looks To Prolong Its Impressive Returns
Aug 10Doximity Faces Slower Revenue Growth As R&D Costs May Rise
Jul 23Is Doximity, Inc. (NYSE:DOCS) Trading At A 23% Discount?
Jul 23At US$27.97, Is It Time To Put Doximity, Inc. (NYSE:DOCS) On Your Watch List?
Jul 01Optimistic Investors Push Doximity, Inc. (NYSE:DOCS) Shares Up 26% But Growth Is Lacking
Jun 09Doximity Earnings: Better Than Expected, But Still Mixed Outlook (Rating Upgrade)
May 17Capital Allocation Trends At Doximity (NYSE:DOCS) Aren't Ideal
May 04Doximity: Significant Upside Remains, But Not Until The Growth Story Returns
Apr 29With Doximity, Inc. (NYSE:DOCS) It Looks Like You'll Get What You Pay For
Apr 16Estimating The Fair Value Of Doximity, Inc. (NYSE:DOCS)
Mar 26Doximity: Rating Upgrade To Buy As Outlook Turns Positive
Feb 21Doximity: Downside Is Contained, While Upside Depends On Management's Game Plan
Jan 16Doximity Earnings: Steer Clear Of This Rollercoaster War Of Optimism Vs. Skepticism
Nov 10Doximity: Adding Value Using AI But Faces Near-Term Risks
Nov 01Doximity: Rating Downgrade As Investors Shift Focus To The Near-Term Outlook
Aug 24Doximity Earnings: Too Many Problems, Sell
Aug 09Doximity: Continue To See Positive Upside From Current Stock Level
Jul 05Doximity: Digital Health Play With Strong Fundamentals
Jun 21Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
3/31/2027 | 713 | 269 | 319 | 328 | 14 |
3/31/2026 | 636 | 224 | 292 | 292 | 19 |
3/31/2025 | 566 | 198 | 259 | 269 | 19 |
12/31/2024 | 550 | 201 | 232 | 239 | N/A |
9/30/2024 | 517 | 174 | 217 | 224 | N/A |
6/30/2024 | 494 | 161 | 162 | 168 | N/A |
3/31/2024 | 475 | 148 | 178 | 184 | N/A |
12/31/2023 | 468 | 138 | 162 | 167 | N/A |
9/30/2023 | 448 | 123 | 160 | 165 | N/A |
6/30/2023 | 437 | 119 | 186 | 192 | N/A |
3/31/2023 | 419 | 113 | 173 | 180 | N/A |
12/31/2022 | 402 | 119 | 173 | 180 | N/A |
9/30/2022 | 384 | 141 | 151 | 159 | N/A |
6/30/2022 | 362 | 148 | 131 | 138 | N/A |
3/31/2022 | 344 | 133 | 121 | 127 | N/A |
12/31/2021 | 317 | 107 | 113 | 117 | N/A |
9/30/2021 | 277 | 57 | 110 | 114 | N/A |
6/30/2021 | 243 | 30 | 103 | 107 | N/A |
3/31/2021 | 207 | 22 | 78 | 83 | N/A |
12/31/2020 | 177 | 14 | 48 | 53 | N/A |
3/31/2020 | 116 | 11 | 22 | 26 | N/A |
3/31/2019 | 86 | 1 | 14 | 15 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DOCS's forecast earnings growth (14.1% per year) is above the savings rate (2.8%).
Earnings vs Market: DOCS's earnings (14.1% per year) are forecast to grow slower than the US market (14.3% per year).
High Growth Earnings: DOCS's earnings are forecast to grow, but not significantly.
Revenue vs Market: DOCS's revenue (11.2% per year) is forecast to grow faster than the US market (8.8% per year).
High Growth Revenue: DOCS's revenue (11.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DOCS's Return on Equity is forecast to be high in 3 years time (21.3%)
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/02/22 11:59 |
End of Day Share Price | 2025/02/21 00:00 |
Earnings | 2024/12/31 |
Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Doximity, Inc. is covered by 28 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Vikram Kesavabhotla | Baird |
Nisala Weerasuriya | Berenberg |
Allen Lutz | BofA Global Research |